[{"id":"147008c9-b17e-4123-a459-475c325f46f7","acronym":"T-START-NR","url":"https://clinicaltrials.gov/study/NCT07470996","created_at":"2026-03-28T01:43:49.187Z","updated_at":"2026-03-28T01:43:49.187Z","phase":"","brief_title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","source_id_and_acronym":"NCT07470996 - T-START-NR","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" ALK negative","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 05/30/2029","primary_completion_date":" 05/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"3bf414c0-2141-4ef6-8218-6aca96f23937","acronym":"CHECK'UP","url":"https://clinicaltrials.gov/study/NCT03412058","created_at":"2021-03-04T17:52:48.409Z","updated_at":"2025-02-25T13:52:30.402Z","phase":"","brief_title":"Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists","source_id_and_acronym":"NCT03412058 - CHECK'UP","lead_sponsor":"UNICANCER","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-20"},{"id":"1a7e9bb9-7b86-4b0f-bf52-ec51de4a9d98","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03113500","created_at":"2021-01-18T15:20:28.612Z","updated_at":"2025-02-25T14:01:16.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03113500 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/25/2017","start_date":" 05/25/2017","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2025-02-19"},{"id":"93d233c8-d3b1-4a92-8fd5-b306320c34dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586999","created_at":"2021-01-18T17:38:33.204Z","updated_at":"2025-02-25T14:27:16.447Z","phase":"Phase 1/2","brief_title":"Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas","source_id_and_acronym":"NCT03586999","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 05/26/2021","primary_completion_date":" 05/26/2021","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2024-10-29"},{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"e704c4fd-c7ac-4597-8954-effccdbd050f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949944","created_at":"2023-07-20T15:09:21.771Z","updated_at":"2024-07-02T16:35:02.840Z","phase":"Phase 1/2","brief_title":"Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT05949944","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-17"},{"id":"d18b18cb-b903-4ed3-9008-7bb395a62471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03297697","created_at":"2021-01-18T16:17:32.348Z","updated_at":"2024-07-02T16:35:03.192Z","phase":"","brief_title":"Minimal Residual Disease in Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03297697","lead_sponsor":"Washington University School of Medicine","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-05-16"},{"id":"0fe10839-16f3-4ebf-97c8-7feb7f85fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083208","created_at":"2021-10-19T15:58:00.734Z","updated_at":"2024-07-02T16:35:05.553Z","phase":"Phase 1/2","brief_title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT05083208","lead_sponsor":"Henan Cancer Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/20/2022","start_date":" 02/20/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-07"},{"id":"1e1f1982-bd28-4ad1-b264-11dd83d52229","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663297","created_at":"2021-01-18T12:58:42.532Z","updated_at":"2024-07-02T16:35:08.127Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","source_id_and_acronym":"NCT02663297","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression • ALK negative • TNFRSF8 negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • ALK negative • TNFRSF8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-04-23"},{"id":"4b00b49c-05e6-4442-a15d-1f3b8ac293cc","acronym":"VALENTINE-PTCL01","url":"https://clinicaltrials.gov/study/NCT04703192","created_at":"2021-01-19T20:51:00.905Z","updated_at":"2024-07-02T16:35:09.833Z","phase":"Phase 2","brief_title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","source_id_and_acronym":"NCT04703192 - VALENTINE-PTCL01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • CD8","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 06/03/2021","start_date":" 06/03/2021","primary_txt":" Primary completion: 05/10/2023","primary_completion_date":" 05/10/2023","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-12"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"39c77db3-f6b0-47a8-808d-f2f9933c2f27","acronym":"GEOMETRY mono-1","url":"https://clinicaltrials.gov/study/NCT02414139","created_at":"2021-01-17T17:12:03.114Z","updated_at":"2024-07-02T16:35:13.913Z","phase":"Phase 2","brief_title":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","source_id_and_acronym":"NCT02414139 - GEOMETRY mono-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 373","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2024-03-20"},{"id":"84a0e5c0-3c01-47ea-b4a2-0d0ce469cdab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05317858","created_at":"2022-04-08T21:52:49.009Z","updated_at":"2024-07-02T16:35:14.930Z","phase":"Phase 3","brief_title":"Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","source_id_and_acronym":"NCT05317858","lead_sponsor":"InSightec","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-13"},{"id":"52396473-78ff-4d4d-a535-0eca9ead2687","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598998","created_at":"2021-01-18T17:41:43.962Z","updated_at":"2024-07-02T16:35:16.011Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas","source_id_and_acronym":"NCT03598998","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Folotyn (pralatrexate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 06/29/2024","study_completion_date":" 06/29/2024","last_update_posted":"2024-03-06"},{"id":"b7ba30e7-e92c-4c59-8947-678e08f35152","acronym":"","url":"https://clinicaltrials.gov/study/NCT04288726","created_at":"2021-01-18T20:48:49.066Z","updated_at":"2024-07-02T16:35:16.521Z","phase":"Phase 1","brief_title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04288726","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2037","study_completion_date":" 06/01/2037","last_update_posted":"2024-03-04"},{"id":"b256a039-fd2a-468d-ac7b-e44e1e11c391","acronym":"KEPIDA-2","url":"https://clinicaltrials.gov/study/NCT05833724","created_at":"2023-04-27T14:05:13.981Z","updated_at":"2024-07-02T16:35:17.751Z","phase":"Phase 2","brief_title":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","source_id_and_acronym":"NCT05833724 - KEPIDA-2","lead_sponsor":"Great Novel Therapeutics Biotech \u0026 Medicals Corporation","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-26"},{"id":"09898f35-b593-4a51-a7e3-509c8daaecd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673785","created_at":"2023-01-06T15:58:43.420Z","updated_at":"2024-07-02T16:35:19.155Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","source_id_and_acronym":"NCT05673785","lead_sponsor":"Takeda","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-16"},{"id":"40c12235-7a66-4e0e-89ba-dbffecad221c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351788","created_at":"2022-04-28T16:57:05.872Z","updated_at":"2024-07-02T16:35:26.230Z","phase":"Phase 2","brief_title":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05351788","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • ALK fusion • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • ALK fusion • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-12-14"},{"id":"bf2c24bb-0980-48a4-95ed-efc1d3846155","acronym":"","url":"https://clinicaltrials.gov/study/NCT02561273","created_at":"2021-01-18T12:24:07.010Z","updated_at":"2024-07-02T16:35:26.335Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy \u0026 Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT02561273","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2023-12-13"},{"id":"fcd0e2ae-efb5-4c64-b0ac-7d867e26098a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05978141","created_at":"2023-08-07T14:08:44.907Z","updated_at":"2024-07-02T16:35:26.304Z","phase":"","brief_title":"A Registry for People With T-cell Lymphoma","source_id_and_acronym":"NCT05978141","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK • CD8","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/27/2030","primary_completion_date":" 07/27/2030","study_txt":" Completion: 07/27/2030","study_completion_date":" 07/27/2030","last_update_posted":"2023-12-13"},{"id":"9af2f6bc-a549-4c5f-a485-f12c6df2bd81","acronym":"CBC","url":"https://clinicaltrials.gov/study/NCT05812534","created_at":"2023-04-13T14:03:28.434Z","updated_at":"2024-07-02T16:35:28.805Z","phase":"Phase 2","brief_title":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","source_id_and_acronym":"NCT05812534 - CBC","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" EGFR","pipe":" | ","alterations":" ALK negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-11-18"},{"id":"52180f19-1459-4ab0-9689-e950c70f09df","acronym":"IMAGINE","url":"https://clinicaltrials.gov/study/NCT05138458","created_at":"2021-12-01T15:53:40.111Z","updated_at":"2024-07-02T16:35:29.495Z","phase":"Phase 1/2","brief_title":"A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL","source_id_and_acronym":"NCT05138458 - IMAGINE","lead_sponsor":"Myeloid Therapeutics","biomarkers":" ALK • CD5","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MT-101"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-13"},{"id":"fcb330ce-34f3-4958-8a53-be2270f787e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01035463","created_at":"2021-01-18T04:03:56.430Z","updated_at":"2024-07-02T16:35:34.269Z","phase":"Phase 1/2","brief_title":"Lenalidomide Therapy After Chemotherapy \u0026 Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01035463","lead_sponsor":"University of Nebraska","biomarkers":" ALK • CD34","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cytarabine • etoposide IV • carmustine • melphalan • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 11/12/2009","start_date":" 11/12/2009","primary_txt":" Primary completion: 07/27/2017","primary_completion_date":" 07/27/2017","study_txt":" Completion: 07/27/2018","study_completion_date":" 07/27/2018","last_update_posted":"2023-10-09"}]